You are here
Report: Blockbuster Drugs Will Drive Immuno-Oncology Market to $34 Billion by 2024
The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, as the treatment of cancer patients undergoes drastic changes over the next decade, according to GlobalData, a research and consulting firm.
The company’s latest report states that the approval and uptake of immuno-oncology products is set to burgeon as a result of increased recognition of their long and durable tumor responses, which are similar to those of targeted therapies. Moreover, these treatments have shown efficacy in a variety of indications and are not associated with the adverse events produced by traditional chemotherapy, such as fatigue, neutropenia, and alopecia.
Senior analyst Dan Roberts, PhD, said: “Immuno-oncology products have demonstrated comparable respective efficacy and safety profiles, so their commercial success will largely rest on the speed with which they enter the market, their clinical and commercial positioning, target patient populations, and the marketing power of the relevant pharmaceutical company.”
Opdivo (nivolumab, Ono/Bristol-Myers Squibb) and Keytruda (pembrolizumab, Schering Plough/Merck) are set to be the highest-selling immuno-oncology drugs, with GlobalData forecasting sales of approximately $10 billion and $7 billion by 2024, respectively.
Roberts explained: “Both therapies, which are programmed cell death protein-1 [PD-1] inhibitors, will achieve such impressive sales due to the fact that they will be first-to-market in many indications, transcending competition, such as Roche’s atezolizumab and AstraZeneca’s durvalumab.
“Although Keytruda will have sales in more tumor types than Opdivo, the indications in which the latter will have an advantage over its competitors will have the largest drug-treated populations, such as non–small-cell lung cancer.”
Roberts added that opportunities for late-to-market entrants will remain, despite the market dominance of a small number of products.
“As PD-1/programmed death ligand-1 [PD-L1] inhibitors eventually saturate the oncology market, new developers are looking for ways to differentiate themselves. One way of doing this is by investigating various combinations of immuno-oncology treatments, with either other immuno-oncology or non–immuno-oncology products.
“AstraZeneca is the company to look out for in regards to the development of novel combinations. Indeed, it has the most late-phase combination trials, predominantly investigating its internally owned immuno-oncology combination product in a number of cancers,” Roberts concluded.
Source: GlobalData; April 19, 2016.